Xencor, Inc. is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics. Xencor’s pipeline features multiple clinical-stage candidates, including bispecific molecules that recruit T cells to tumor cells and antibody therapeutics targeting checkpoint pathways. The company also explores next-generation cytokine fusions designed to improve safety and efficacy profiles over conventional formats.
In advancing its discovery programs, Xencor has established strategic collaborations and licensing agreements with several leading pharmaceutical companies. Partners include Amgen, Pfizer, AstraZeneca and Lilly, among others, which leverage Xencor’s XmAb® platform to generate novel candidates across oncology, inflammation and immunology. Through these partnerships, Xencor’s technology reaches global markets via co-development and commercial licensing arrangements.
Founded in 1997 and headquartered in Monrovia, California, Xencor is led by President and Chief Executive Officer Bassil Dahiyat, Ph.D., who co-founded the company with a vision to harness protein engineering for therapeutic innovation. Over its history, Xencor has grown from a technology-focused startup into a specialized biotech organization advancing multiple clinical programs toward regulatory milestones.
AI Generated. May Contain Errors.
